CEO John Varian unloaded 10,000 shares of XOMA Corp (NASDAQ:XOMA) stock on the open market in a transaction that occurred on Thursday, May 15th. The shares were sold at an average price of $3.55, for a total transaction of $35,500.00. XOMA Corp (NASDAQ:XOMA) weekly performance is 4.66%. On last trading day company shares ended up $3.59. Analysts mean target price for the company is $9.25. XOMA Corp (NASDAQ:XOMA) distance from 50-day simple moving average (SMA50) is -27.08%.
Questcor Pharmaceuticals (NASDAQ:QCOR) CEO Don M. Bailey sold 40,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 13th. The stock was sold at an average price of $87.05, for a total value of $3,482,000.00. Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) shares advanced 1.46% in last trading session and ended the day on $88.43. QCOR gross Margin is 91.10% and its return on assets is 46.90%.Questcor Pharmaceuticals Inc. (NASDAQ:QCOR) quarterly performance is 27.57%.
InterMune (NASDAQ:ITMN) VP Sean Nolan sold 2,644 shares of InterMune stock in a transaction dated Thursday, May 8th. The stock was sold at an average price of $35.85, for a total value of $94,787.40. Following the completion of the sale, the vice president now directly owns 72,556 shares of the company’s stock, valued at approximately $2,601,133. InterMune Inc. (NASDAQ:ITMN) shares moved down -1.13% in last trading session and was closed at $35.01, while trading in range of $33.67 – $35.20. InterMune Inc. (NASDAQ:ITMN) year to date (YTD) performance is 137.68%.
Alexion Pharmaceuticals (NASDAQ:ALXN) Director Alvin S. Parven unloaded 12,276 shares of the stock in a transaction dated Tuesday, May 13th. The stock was sold at an average price of $160.78, for a total value of $1,973,735.28. Following the transaction, the director now directly owns 4,840 shares of the company’s stock, valued at approximately $778,175. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) ended the last trading day at $157.71. Company weekly volatility is calculated as 3.95% and price to cash ratio as 20.03.Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) showed a positive weekly performance of 4.41%.
Illumina (NASDAQ:ILMN) CFO Marc Stapley unloaded 1,422 shares of the stock in a transaction that occurred on Wednesday, May 14th. The shares were sold at an average price of $146.94, for a total value of $208,948.68. Following the completion of the sale, the chief financial officer now directly owns 21,996 shares of the company’s stock, valued at approximately $3,232,092. Illumina, Inc. (NASDAQ:ILMN) net profit margin is 13.80% and weekly performance is 3.45%. On last trading day company shares ended up $144.75. Analysts mean target price for the company is $176.97. Illumina, Inc. (NASDAQ:ILMN) distance from 50-day simple moving average (SMA50) is -2.35%.